



NEW IMPROVED PLATELET LYSATES FOR: NEUROPROTECTION, NEURORESTORATION AND NEUROGENESIS



Keywords

- Platelet lysates
- Neuroprotection
- Neurodegenerative diseases
- Amyotrophic Lateral Sclerosis



Intellectual Property

European patent filed on March 23, 2016



Development Status

POC in vitro/in vivo
Pre clinical



Partnership

Partnerships to achieve the development in the best therapeutic application and/or out-licensing


Technology

Platelets constitute abundant, natural, readily accessible sources of physiological mixtures of numerous growth factors (GFs) with proven effects on cell survival and proliferation.

Platelet lysates (PL) are already used in several fields of human regenerative medicine as well as for cell therapy procedures.

In particular, PLs contain a physiological balance of neurotrophic GFs thought to regulate the development, maintenance, function and plasticity of the vertebrate nervous system.

Improved PLs produced in the laboratory can potentially be used as disease-modifying strategy for the treatment of neurodegenerative disorders.



Benefits

- **Improved PLs** are more active than classical PL or single GF
- Less toxic at high dosage than classical PL
- Neuroprotection
- Efficient on an in-vivo model of Parkinson's disease
- Platelets abundance

Applications

- ALS treatment
- Neurodegenerative diseases treatment
- Treatment for neurological diseases

contact

Yannick Campion

Business Developer

+33 6 13 84 38 04

yannick.campion@sattnord.fr

find other technologies on
www.sattnord.fr



SATT Nord

25, avenue Charles St Venant – 59800 LILLE – France

+33 3 28 36 04 68 – tech@sattnord.fr